ELV Elevance Health, Inc. Insider Trading

Director Ramiro G Peru purchases 1.0K shares of ELV at $366.05, raising stake to 10.9K shares

Ramiro G Peru, a director of Elevance Health, Inc., purchased 1,000 shares at $366.05 on 2026-07-17, increasing his holdings by +10.1% to 10.9K shares. The stock currently trades at $369.40, and the company reports solid fundamentals with $50.5B revenue, $1.5B net income, and 12.5% annual revenue growth at a P/E of 16.15. However, Peru's cross-ticker track record reveals a concerning pattern: across his open-market trading history, his 1 prior buy generated an average 90-day return of -16.7% with a 0.00% win rate, suggesting this purchase aligns with his pattern of unfavorable timing. The stock itself is -15.3% from its 52-week high and down 5.6% over 30 days despite the 14.4% 90-day gain, warranting close observation of whether this transaction precedes further weakness or stabilization.

Gail Boudreaux (CEO) buys 2,725 shares of ELV for $1,002,230.05; all 5 prior trades at this ticker well-timed.

Gail Boudreaux, President and CEO of Elevance Health, executed 2 separate purchases on 2026-07-17 totaling 2,725 shares for $1,002,230.05 at a blended average price of $367.79, increasing her holdings by 1.6% to 172.0K shares. The timing is noteworthy: the stock is currently trading at $369.40, down 15.3% from its 52-week high of $436.24 and down 5.6% over the prior 30 days, yet up 14.4% over 90 days. Across her 5 prior trades at Elevance Health, Boudreaux has demonstrated perfect execution; her 3 prior buys at ELV each posted positive 90-day returns (20.9%–21.7%), and her 2 prior sells both posted negative 90-day returns (−13.9% and −14.6%), yielding a 100% well-timed rate at this ticker. The company reports strong fundamentals with $50.5B in annual revenue, $1.5B net income, 12.5% year-over-year revenue growth, and a P/E of 16.15, providing no apparent distress signal underlying this purchase.

Penczek Ronald W (CAO & Controller) sold 1,531 shares of ELV at $403.13 on 2026-05-19; holds 4,109 shares post-sale

Penczek Ronald W, CAO & Controller, sold 1,531 shares totaling $617,192.03 at $403.13 per share, reducing his position by 27.1%. The transaction occurred near the 52-week high of $412.96, with the stock currently trading at $396.02. His cross-ticker track record shows only 1 prior sell, and his prior trade at ELV (a sell on 2023-11-30) has no measurable outcome yet, providing limited context for assessing timing patterns at this ticker. With Elevance Health trading at a P/E of 16.41 and posting quarterly revenue of $50,181,000,000.00 with net income of $1,764,000,000.00, the company shows solid fundamentals and 12.5% annual revenue growth.

EVP & President (Commercial) Kendrick Charles Morgan JR sold 3,196 shares of ELV at $284.92 on 2026-03-06; stock down -38.0% from 52-week high.

Kendrick Charles Morgan JR, EVP & President (Commercial) at Elevance Health, sold 3,196 shares for $910,604.32, reducing his holdings by 21.3%. The sale occurred at $284.92 per share; the stock has since fallen to $280.74 and is trading -38.0% below its 52-week high of $452.69, with a -17.2% decline over the prior 30 days. Notably, at this same ticker, his prior three sales showed mixed timing outcomes: the 2025-03-05 and 2024-03-08 sales were followed by positive 30-day returns, while the 2024-10-18 sale was followed by negative returns at both 30- and 90-day windows, with 2 of 3 prior ELV sales well-timed at the 90-day mark. His cross-ticker track record shows 3 prior sells with a 66.67% well-timed rate at 90 days, though the average 90-day return was -2.4%. The company's fundamentals remain solid—$50.7B in latest quarterly revenue, $1.2B net income, +12.5% annual revenue growth, and an 11.88 P/E ratio—warranting examination of whether the sale reflects portfolio management amid the recent sharp equity decline or other factors.

Director Collis Steven H buys 3,000 shares of ELV at $289.84, tripling holdings to 3,639 shares (+469.5%)

Director Collis Steven H purchased 3,000 shares of Elevance Health for $869,520.00 on 2026-03-05, increasing his holdings from 639 to 3,639 shares—a 469.5% increase from his prior position. The purchase occurred at $289.84 per share, while the stock trades at $289.64 today, approximately 36.0% below its 52-week high of $452.69 and down 15.0% over the past 30 days. The company trades at a 12.26 P/E with solid fundamentals ($50.7B quarterly revenue, $1.2B net income, 12.5% annual growth). Notably, across his cross-ticker open-market history, this director has completed only 1 prior buy against 19 prior sells; his sell-timing record shows a 26.32% well-timed rate and 5.9% average 90-day return, indicating his historical sales have generally been followed by further declines. This buy represents a material shift in activity pattern and a substantial increase in personal position concentration.

Director DeVore purchases 1,200 shares of ELV for $374.6K, raising holdings 52.1% to 3.5K shares

Susan D. DeVore, a director at Elevance Health, acquired 1,200 shares at $312.15 on 2025-08-19, increasing her post-transaction holdings to 3,502 shares from 2,302 shares—a 52.1% increase in her personal stake. The stock is currently trading at $309.60, below the transaction price and -44.9% from its 52-week high of $562.29, though it has recovered +9.9% over the past 30 days. With Elevance trading at a 13.01 P/E ratio and generating $1.7B in net income on $49.8B in quarterly revenue, the company represents a large-cap health insurance player. The director's substantial proportional increase in holdings occurred during a period of stock weakness relative to recent highs, warranting attention to whether this reflects conviction in valuation or represents a scheduled transaction unrelated to near-term price outlook.

CEO Gail Boudreaux bought 8,500 shares for $2,438,951.30 at $286.94 (blended) as ELV stock down 26.3% in 30 days, 34.7% in 90 days.

On 2025-07-18, Elevance Health CEO Gail Boudreaux executed 3 open-market purchases totaling 8,500 shares for $2,438,951.30 at a blended average price of $286.94, increasing her holdings from 142,520 to 151,020 shares. The timing is notable: the stock has declined 26.3% in the prior 30 days and 34.7% in the prior 90 days from a 52-week high of $562.29, now trading at $277.09—a 3% discount to the transaction price. This is Boudreaux's first open-market buy activity flagged in the filing; her prior 5 trades at ELV (all in July 2024) were sales, and her cross-ticker track record of 6 prior sales achieved a 100% well-timed rate (all 5 same-ticker sales were followed by stock declines). The Company itself remains fundamentally solid with $49.8B in annual revenue, $1.7B net income, and a 11.64 P/E ratio, suggesting the recent selloff may have created a valuation opportunity. The divergence between the insider's historical pattern (well-timed exits) and this discretionary buy into a steep drawdown warrants attention to whether this signals a shift in conviction or is simply a redeployment of capital at compressed valuations.

CFO Mark Kaye sold 4,588 shares of ELV at $424.82 on 2025-04-24 for $1,949,074.16; holds 18,977 shares post-sale.

Kaye Mark, EVP & CFO, executed a sale reducing his holdings by 19.5%, from 23,565 shares to 18,977 shares. The sale occurred at $424.82 per share while the stock currently trades at $421.68, placing the executed price near recent levels but 25.0% below the 52-week high. Across his six prior open-market sales on other tickers, the cross-ticker track record shows a 100.00% well-timed rate with an average 90-day return of -2.8%, indicating historically favorable exit timing. The company's fundamentals remain solid with $48.9B in revenue, $2.2B net income, and a moderate 16.10 P/E ratio, suggesting no obvious distress signal from the transaction itself.

EVP & President Morgan sells 3,504 ELV shares at $396.30; stock -29.3% from 52-week high

Kendrick Charles Morgan JR, EVP & President of Commercial at Elevance Health, sold 3,504 shares (3.5K shares) for $1,388,635.20 on 2025-03-05, reducing his holdings by -25.7% from 13,620 to 10,116 shares. The sale occurred at $396.30, while the stock now trades at $397.47 and is -29.3% from its 52-week high of $562.29, indicating material weakness in ELV's valuation since peak. His prior two sales at ELV (2024-10-18 and 2024-03-08) showed mixed outcomes: the October 2024 sale was followed by a -10.8% 90-day decline (well-timed), while the March 2024 sale saw a +8.1% 90-day gain (poorly timed); across all tickers, his 50.00% well-timed rate on sells does not indicate a strong pattern of prescience. The company's fundamentals remain solid (P/E 14.09, $45.1B revenue, +3.3% annual growth, $1.0B net income), but the sale's scale—representing a meaningful reduction in his direct equity stake—warrants observation for any shift in his conviction at a company where he holds a senior operational role.

EVP & President Kendrick Morgan sold 7,417 ELV shares at $432.14 on 2024-10-18, retaining 8,423 shares post-transaction.

Kendrick Charles Morgan JR, EVP & President of Commercial at Elevance Health, executed a sale of 7,417 shares valued at $3,205,182.38, reducing his holdings by -46.8% to 8,423 shares. The transaction occurred at $432.14, and the stock has since declined -20.2% over the past 30 days and -23.4% from its 52-week high of $562.29. His prior sell at ELV on 2024-03-08 generated positive 90-day returns (+8.1%), indicating the earlier sale preceded a rise in stock price—a poorly timed outcome for capturing downside. The current sale occurs in a context of significant recent weakness, yet the insider's historical track record at this ticker shows no pattern of well-timed sells (0 of 1 prior sells were well-timed at the 90-day mark). The company's fundamentals remain stable with $45.1B revenue, +9.4% annual growth, and a P/E of 15.57, offering limited fundamental justification for the magnitude of recent price deterioration.